Fibrin Metabolism in Patients with Acute Myocardial Infarction During and After Treatment with Tissue-Type Plasminogen Activator

Summary

In order to define some of the determinants of successful thrombolysis and reocclusion during fibrinolytic therapy for acute myocardial infarction (AMI), specific molecular markers of fibrin metabolism were serially measured in 15 patients with AMI treated with tissue-type plasminogen activator (t-PA). Fibrin formation was assessed by measurement of fibrinopeptide A (FpA) and fibrinolysis by assay of B-P peptides 1—42 and 15—42 and crosslinked fibrin degradation products (XDP). At baseline, FpA levels were high while markers of fibrinolysis were near normal. Following a 90-minute infusion of t-PA (0.5—1.1 mg kg⁻¹ hr⁻¹), all markers of fibrinolysis increased. Levels of FpA remained elevated despite heparin at the initiation of cardiac catheterization. None of these markers discriminated between patients with successful reperfusion from those without. At 4 hours, B-β 15—42 peptide and XDP levels remained elevated suggesting persistence of fibrinolysis beyond the short circulatory half-life of t-PA. FpA levels at 4 hours were lower in patients who underwent acute coronary angioplasty compared to those who received additional low dose t-PA (12.3 ± 4.5 vs. 30.4 ± 5.5 ng/ ml, p <0.05). By 48 hours, markers of fibrinolysis had returned toward normal except in 2 patients with persistently elevated B-P 15—42 peptide levels who suffered reocclusion on days 5 and 6 (75 and 44 vs. 29 ± 3 nM, p <0.005). In conclusion, molecular markers of fibrin metabolism during fibrinolytic therapy may provide clinically relevant data.

Keywords

Fibrinolytic therapy - Tissue - type plasminogen activator - Acute myocardial infarction - Plasminogen activator inhibitor - Percutaneous transluminal coronary angioplasty - Fibrin metabolism

• References

• 1 TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985 312. 932-936
• 2 Simmoons ML, Serruys PW, Brand M. v/d, et al Improved survival after early thrombolysis in acute myocardial infarction. A randomized trial conducted by the Interuniversity Cardiology Institute in The Netherlands. Lancet 1985 2. 578-582
• 3 Gruppo Italiano Per Lo Studio Della Streptchiasi Nell’ Infarcto Miacardico (GISSI). Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet 1986 1. 397-401
• 4 Schaer DH, Ross AM, Wasserman AG. Reinfarction, recurrent angina, anil reocclusion after thrombolytic therapy. Circulation 1987; (Suppl. 76) suppl II II: 57-62
• 5 Blombiick B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978; 275: 501-505
• 6 Chen R, Dolittle RF. τ-τ Cross-linking sites in human and bovine fibrin. kBiochemistry 1971; 10: 4486-4491
• 7 Nossel HL, Younger LR, Wilner GD, Procupez T, Canfield RE, Butler VP. Radioimmunoassay of human tibrinopeptide A. Proc Natl Acad Sci 1971; 68: 2350-2353
• 8 Nossel HL, Yudelman I, Canfield RE. et al Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53
• 9 Kockum C. Radioimmunoassay of fibrinopeptide A: clinical applications. Thromb Res 1976; 8: 225-236
• 10 Yudelman IM, Nossel HL, Kaplan KL I, Hirch J. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood 1978; 51: 1189-1195
• 11 Gaffney PJ, Perry MJ. Unreliability of current serum fibrin degradation product (FDP) assays. Thromb Haemostas 1985; 53: 301-302
• 12 Sherry S. Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction?. Am J Cardiol 1987; 59: 984-989
• 13 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. A monoclonal antibody with ability to distinguish between NH₂-terminal fragments derived from fibrinogen and fibrin. Molec Immun 1983; 20: 1191-2000
• 14 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH₂-terminal region of fibrin. Molec Immun 1984; 21: 89-94
• 15 Rylatt DB, Blake AS, Cottis LE. et al An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983; 37: 767-718
• 16 Whitaker AN, Elms MJ, Masci PP. et al Measurement of cross linked fibrin derivatives in plasma: an immunoassay using monoclonal antibodies. J Clin Pathol 1984; 37: 882-887
• 17 Elms MJ, Bunce IH, Bundesen PG. et al Measurement of crosslinked fibrin degradation products an immunoassay using monoclonal antibodies. Thromb Haemostas 1983; 50: 591-594
• 18 Hunt FA, Rylatt DB, Hart RA, Bundesen PG. Serum crosslinked fibrin (XDP) and fibrinbgen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems. Br J Haematol 1985; 60: 715-722
• 19 Verstraete M, Bounameaux H, de Cock F, Van de Werf E, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985; 235: 506-512
• 20 Mombelli G, Im Hof V, Haeberli A, Straub PW. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction. Circulation 1984; 69: 684-689
• 21 Johnson H, Orinius E, Paul C. Fibrinopeptide A (FPA) in patients with acute myocardial infarction. Thromb Res 1979; 16: 255-260
• 22 Gallino A, Haeberli A, Baur HR, Straub PW. Fibrin formation and platelet aggregation in patients with severe coronary artery disease: relationship with the degree of myocardial ischemia. Circulation 1985; 72: 27-30
• 23 Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrinopeptide A: a marker of acute coronary thrombosis. Circulation 1985; 71: 912-918
• 24 Lew AS, Berberian L, Cercek B, Lee S, Shah PK, Ganz W. Elevated serum D dimer: a degradation product of crosslinked fibrin (XDP) after intravenous streptokinase during acute myocardial infarction. J Am Coll Cardiol 1986; 7: 1320-1324
• 25 Eisenberg PR, Sherman LA, Perez J, Jaffe AS. Relationship between elevated plasma levels of crosslinked fibrin degradation products (xl-FDP) and the clinical presentation of patients with myocardial infarction. Thromb Res 1987; 46: 109-120
• 26 Eisenberg PR, Sherman LA, Jaffe AS. Differentiation of fibrinolysis from fibrinogenolysis with B-β 1-42 and B-β 15-42. Circulation 1986; (Suppl. 74) suppl II II-245 abstr
• 27 Nossel HL, Wasser J, Kaplan KL, LaGamma KS, Yudelman I, Canfield RE. Sequence of fibrinogen proteolysis and platelet release after intrauterine infusion of hypertonic saline. J Clin Invest 1979; 64: 1371-1378
• 28 Pizzo SV, Schwartz ML, Hill RL, McKee PA. The effect of plasmin on the subunit of fibrinogen. J Biol Chem 1972; 247: 636-645
• 29 Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. J Clin Invest 1987; 79: 1642-1647
• 30 Frances CW, Connaghan G, Marder VJ. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. Circulation 1986; 5: 1027-1036
• 31 Seifried E, Thnswell P, Rijken DC, Kluft C, Hoegee E, Nieuwenhuizen W. Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction. Lancet 1987; II: 333-334 letter
• 32 Eisenberg PR, Sherman LA, Tiefenbrunn AJ, Ludbrook PA, Sobel BE, Jaffe AS. Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation. Thromb Haemostas 1987; 57: 35-40
• 33 Nieuwenhuizen W, Emeis JJ, Vermond A. Catabolism of purified rat fibrin(ogen) plasmin degradation products in rats. Thromb Res 1975; 48: 59-61
• 34 Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss AJ. D-pheproarg-chloromethylketone: Its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemostas 1986; 56: 160-164
• 35 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor tibrinogen breakdown during t-PA infusion. Blood 1986; 67: 1482-1487
• 36 Nichols AB, owen J, Giossman BA, Marcella JJ, Fleisher LN, Lee MM L. Effect of heparin bonding on catheter-induced fibrinformation and platelet activation. Circulation 1984; 70: 843-850